Mortality in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Media type: E-Article

Title: Mortality in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Contributor: Banerji, Mary Ann; Buse, John B.; Younes, Naji; Krause-Steinrauf, Heidi; Ghazi, Adline; Lee, Melissa; Park, Jean; Pop-Busui, Rodica; Underkofler, Chantal; Fortmann, Stephen P.; Crandall, J.P.; McKee, M.D.; Behringer-Massera, S.; Brown-Friday, J.; Xhori, E.; Ballentine-Cargill, K.; Duran, S.; Estrella, H.; Gonzalez de la torre, S.; Lukin, J.; Phillips, L.S.; Burgess, E.; Olson, D.; Rhee, M.; [...]

Published: American Diabetes Association, 2024

Language: English

DOI: 10.2337/dc23-1356

ISSN: 0149-5992; 1935-5548

Origination:

Footnote:

Description: OBJECTIVE We report mortality outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) among people with type 2 diabetes diagnosed within 10 years and no recent history of cardiovascular events or cancer. RESEARCH DESIGN AND METHODS Overall mortality rates and major causes of death were assessed over an average of 5 years of follow-up. Cause of death was adjudicated centrally by a committee masked to treatment assignment. We examined baseline covariates and the 10-year Framingham Risk Score for associations. RESULTS Mortality rate was low (0.59 per 100 participant-years). Participants who died during follow-up were likely to be older, be male, have a history of hypertension, have a history of smoking, and have moderate albuminuria. The two most common underlying causes of death were “cardiovascular-cause” (a composite of underlying causes) (38.6%) and cancer (26.8%). There were no differences by treatment group. CONCLUSIONS Among people with diabetes of relatively short duration, cause of death was varied. Attention to health risks beyond cardiovascular diseases is warranted.

Search in field:

Recently searched for: